Lipids in Alzheimer’s disease and their potential for therapy

References

• Holtzman DM, Morris JC, Goate AM. Alzheimer’s disease: the challenge of the second century. Sci. Transl. Med. 3(77), 77sr71 (2011).
   Google Scholar
• Di Paolo G, Kim TW. Linking lipids to Alzheimer’s disease: cholesterol and beyond. Nat. Rev. Neurosci. 12(5), 284–296 (2011).
   Google Scholar
• Mielke MM, Lyketsos CG. Lipids and the pathogenesis of Alzheimer’s disease: is there a link? Int. Rev. Psychiatry 18(2), 173–186 (2006).
   Google Scholar
• Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Neurologisches Zentralblatt 23, 1129–1136 (1906).
   Google Scholar
• Walter J. Gamma-secretase, apolipoprotein E and cellular cholesterol metabolism. Curr. Alzheimer Res. doi:BSP/CAR/E-Pub/00047 (2011) (Epub ahead of print).
   Google Scholar
• Teoh CL, Griffin MD, Howlett GJ. Apolipoproteins and amyloid fibril formation in atherosclerosis. Protein Cell 2(2), 116–127 (2011).
   Google Scholar
• He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer’s disease. Neurobiol. Aging 31(3), 398–408 (2010).
   Google Scholar
• Conti E, Galimberti G, Piazza F, Raggi ME, Ferrarese C. Increased soluble APPalpha, Abeta 1–42, and anti-Abeta 1–42 antibodies in plasma from down syndrome patients. Alzheimer Dis. Assoc. Disord. 24(1), 96–100 (2010).
   Google Scholar
• Vassar R. Beta-secretase (BACE) as a drug target for Alzheimer’s disease. Adv. Drug Deliv. Rev. 54(12), 1589–1602 (2002).
   Google Scholar
• Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. Reconstitution of gamma-secretase activity. Nat. Cell. Biol. 5(5), 486–488 (2003).
   Google Scholar
• Ashe KH. A tale about tau. N. Engl. J. Med. 357(9), 933–935 (2007).
   Google Scholar
• Rapoport SI. In vivo fatty acid incorporation into brain phosholipids in relation to plasma availability, signal transduction and membrane remodeling. J. Mol. Neurosci. 16(2–3), 243–261; discussion 279–284 (2001).
   Google Scholar
• Haughey NJ, Bandaru VV, Bae M, Mattson MP. Roles for dysfunctional sphingolipid metabolism in Alzheimer’s disease neuropathogenesis. Biochim. Biophys. Acta 1801(8), 878–886 (2010).
   Google Scholar
• Prasad MR, Lovell MA, Yatin M, Dhillon H, Markesbery WR. Regional membrane phospholipid alterations in Alzheimer’s disease. Neurochem. Res. 23(1), 81–88 (1998).
   Google Scholar
• Cutler RG, Haughey NJ, Tammara A et al. Dysregulation of sphingolipid and sterol metabolism by ApoE4 in HIV dementia. Neurology 63(4), 626–630 (2004).
   Google Scholar
• Haughey NJ. Sphingolipids in neurodegeneration. Neuromolecular Med. 12(4), 301–305 (2010). Effectively describes the role of sphingolipids in neurodegenerative processes.
   Google Scholar
• Haughey NJ, Cutler RG, Tamara A et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann. Neurol. 55(2), 257–267 (2004).
   Google Scholar
• Darios F, Wasser C, Shakirzyanova A et al. Sphingosine facilitates SNARE complex assembly and activates synaptic vesicle exocytosis. Neuron 62(5), 683–694 (2009).
   Google Scholar
• Blochl A, Thoenen H. Localization of cellular storage compartments and sites of constitutive and activity-dependent release of nerve growth factor (NGF) in primary cultures of hippocampal neurons. Mol. Cell. Neurosci. 7(3), 173–190 (1996).
   Google Scholar
• Jeon HJ, Lee DH, Kang MS et al. Dopamine release in PC12 cells is mediated by Ca2+-dependent production of ceramide via sphingomyelin pathway. J. Neurochem. 95(3), 811–820 (2005).
   Google Scholar
• Numakawa T, Nakayama H, Suzuki S et al. Nerve growth factor-induced glutamate release is via p75 receptor, ceramide, and Ca2+ from ryanodine receptor in developing cerebellar neurons. J. Biol. Chem. 278(42), 41259–41269 (2003).
   Google Scholar
• Cutler RG, Kelly J, Storie K et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc. Natl Acad. Sci. USA 101(7), 2070–2075 (2004).
   Google Scholar
• Joseph JA, Denisova NA, Bielinski D, Fisher DR, Shukitt-Hale B. Oxidative stress protection and vulnerability in aging: putative nutritional implications for intervention. Mech. Ageing Dev. 116(2–3), 141–153 (2000).
   Google Scholar
• Han X, D MH, Mckeel DW Jr, Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis. J. Neurochem. 82(4), 809–818 (2002).
   Google Scholar
• Satoi H, Tomimoto H, Ohtani R et al. Astroglial expression of ceramide in Alzheimer’s disease brains: a role during neuronal apoptosis. Neuroscience 130(3), 657–666 (2005).
   Google Scholar
• Mielke MM, Haughey NJ, Ratnam BVV et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 6(5), 378–385 (2010). Describes a plausible new marker for the prediction of Alzheimer’s disease in an early state.
   Google Scholar
• Slotte JP. Cholesterol–sphingomyelin interactions in cells – effects on lipid metabolism. Subcell. Biochem. 28, 277–293 (1997).
   Google Scholar
• Ahmed SN, Brown DA, London E. On the origin of sphingolipid/cholesterol-rich detergent-insoluble cell membranes: physiological concentrations of cholesterol and sphingolipid induce formation of a detergent-insoluble, liquid-ordered lipid phase in model membranes. Biochemistry 36(36), 10944–10953 (1997).
   Google Scholar
• Yu ZF, Nikolova-Karakashian M, Zhou D, Cheng G, Schuchman EH, Mattson MP. Pivotal role for acidic sphingomyelinase in cerebral ischemia-induced ceramide and cytokine production, and neuronal apoptosis. J. Mol. Neurosci. 15(2), 85–97 (2000).
   Google Scholar
• Opreanu M, Tikhonenko M, Bozack S et al. The unconventional role of acid sphingomyelinase in regulation of retinal microangiopathy in diabetic human and animal models. Diabetes 60(9), 2370–2378 (2011).
   Google Scholar
• Grimm MO, Grimm HS, Pätzold AJ et al. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin. Nat. Cell Biol. 7(11), 1118–1123 (2005).
   Google Scholar
• Sawamura N, Ko M, Yu W et al. Modulation of amyloid precursor protein cleavage by cellular sphingolipids. J. Biol. Chem. 279(12), 11984–11991 (2004).
   Google Scholar
• Huang Y, Tanimukai H, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. Elevation of the level and activity of acid ceramidase in Alzheimer’s disease brain. Eur. J. Neurosci. 20(12), 3489–3497 (2004).
   Google Scholar
• Hung WC, Chang HC, Chuang LY. Activation of caspase-3-like proteases in apoptosis induced by sphingosine and other long-chain bases in Hep3B hepatoma cells. Biochem. J. 338(Pt 1), 161–166 (1999).
   Google Scholar
• Sweeney EA, Inokuchi J, Igarashi Y. Inhibition of sphingolipid induced apoptosis by caspase inhibitors indicates that sphingosine acts in an earlier part of the apoptotic pathway than ceramide. FEBS Lett. 425(1), 61–65 (1998).
   Google Scholar
• Hagen N, Hans M, Hartmann D, Swandulla D, van Echten-Deckert G. Sphingosine-1-phosphate links glycosphingolipid metabolism to neurodegeneration via a calpain-mediated mechanism. Cell Death Differ. 18(8), 1356–1365 (2011).
   Google Scholar
• van Echten-Deckert G, Herget T. Sphingolipid metabolism in neural cells. Biochim. Biophys. Acta 1758(12), 1978–1994 (2006).
   Google Scholar
• Hagen N, Van Veldhoven PP, Proia RL, Park H, Merrill AH Jr, Van Echten-Deckert G. Subcellular origin of sphingosine 1-phosphate is essential for its toxic effect in lyase-deficient neurons. J. Biol. Chem. 284(17), 11346–11353 (2009).
   Google Scholar
• Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. 278(48), 47408–47415 (2003).
   Google Scholar
• Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277(24), 21453–21457 (2002).
   Google Scholar
• Lahiri S, Park H, Laviad EL, Lu X, Bittman R, Futerman AH. Ceramide synthesis is modulated by the sphingosine analog FTY720 via a mixture of uncompetitive and noncompetitive inhibition in an Acyl-CoA chain length-dependent manner. J. Biol. Chem. 284(24), 16090–16098 (2009). Describes the inhibitory effects of a synthetic substance on ceramide synthesis.
   Google Scholar
• Berdyshev EV, Gorshkova I, Skobeleva A et al. FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells. J. Biol. Chem. 284(9), 5467–5477 (2009).
   Google Scholar
• Amenta F, Tayebati SK. Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction. Curr. Med. Chem. 15(5), 488–498 (2008).
   Google Scholar
• Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst. Rev. 3, CD001015 (2003).
   Google Scholar
• Heron DS, Shinitzky M, Hershkowitz M, Samuel D. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc. Natl Acad. Sci. USA 77(12), 7463–7467 (1980).
   Google Scholar
• Bourre JM, Dumont O, Piciotti M et al. Essentiality of omega 3 fatty acids for brain structure and function. World Rev. Nutr. Diet 66, 103–117 (1991).
   Google Scholar
• Astarita G, Piomelli D. Towards a whole-body system [multi-organ] lipidomics in Alzheimer’s disease. Prostaglandins Leukot. Essent. Fatty Acids 85(5), 197–203 (2011).
   Google Scholar
• Green KN, Martinez-Coria H, Khashwji H et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving persenilin 1 levels. J. Neurosci. 27, 4385–4395 (2007).
   Google Scholar
• Hooijmans CR, Rutters F, Dederen PJ et al. Changes in cerebral blood volume and amyloid pathology in aged Alzheimer APP/PS1 mice on a docosahexaenoic acid (DHA) diet or cholesterol enriched typical western diet (TWD). Neurobiol. Dis. 28, 16–29 (2007).
   Google Scholar
• Oksman M, Iivonen H, Hogyes E et al. Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice. Neurobiol. Dis. 23, 563–572 (2006). Describes the impact of fatty acids on amyloid-b accumulation.
   Google Scholar
• Lukiw WJ, Cui JG, Marcheselli VL et al. A role for docosahexaenoic acid-derived neuroprotecting D1 in neural cell survival and Alzheimer’s disease. J. Clin. Invest. 115, 2774–2783 (2005).
   Google Scholar
• Stillwell W, Shaikh SR, Zerouga M, Siddiqui R, Wassall SR. Docosahexaenoic acid affects cell signaling by altering lipid rafts. Reprod. Nutr. Dev. 45(5), 559–579 (2005).
   Google Scholar
• Cole GM, Frautschy SA. DHA may prevent age-related dementia. J. Nutr. 140(4), 869–874 (2010).
   Google Scholar
• Ma QL, Yang F, Rosario ER et al. Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J. Neurosci. 29, 9078–9089 (2009).
   Google Scholar
• Quinn JF, Raman R, Thomas RG et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA 304(17), 1903–1911 (2010).
   Google Scholar
• Hashimoto M, Hossain S, Shimada T et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer’s disease model rats. J. Neurochem. 8(5), 1084–1091 (2002).
   Google Scholar
• Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscl. Thromd. Vasc. Biol. 24, 806–815 (2004).
   Google Scholar
• Dietschy JM, Turley SD. Cholesterol metabolism in central nervous system during early development and in the mature animal. J. Lipid Res. 45, 1375–1397 (2004).
   Google Scholar
• Puglielli L, Konopka G, Pack-Chung E et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat. Cell Biol. 3(10), 905–912 (2001).
   Google Scholar
• Bhattacharyya R, Kovacs DM. ACAT inhibition and amyloid beta reduction. Biochim. Biophys. Acta 1801(8), 960–965 (2010).
   Google Scholar
• Hutter-Paier B, Huttunen HJ, Puglielli L et al. The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer’s disease. Neuron 44(2), 227–238 (2004).
   Google Scholar
• Björkhem I, Cedazo-Minguez A, Leoni V, Meaney S. Oxysterols and neurodegenerative diseases. Mol. Asp. Med. 30, 171–179 (2009).
   Google Scholar
• Puglielli L, Tanzi RE, Kovacs DM. Alzheimer’s disease: the cholesterol connection. Nat. Neurosci. 6, 345–351 (2003).
   Google Scholar
• Simons M, Keller P, Destrooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc. Natl Acad. Sci. USA 95, 6460–6464 (1998).
   Google Scholar
• Xiong H, Callaghan D, Jones A et al. Cholesterol retention in Alzheimer’s brain is responsible for high beta- and gamma-secretase activities and A-beta production. Neurobiol. Dis. 29, 422–437 (2008).
   Google Scholar
• Crameri A, Biondi E, Kuehnle K et al. The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and A-beta generation in vivo. EMBO J. 25, 432–443 (2006).
   Google Scholar
• Galloway S, Jian L, Johnsen R, Chew S, Mamo JCL. Beta-amyloid or its precursor protein is found in epithelial cells of the small intestine and is stimulated by high-fat feeding. J. Nutr. Biochem. 18, 279–284 (2007).
   Google Scholar
• Fernández A, Llacuna L, Fernánez-Checa JC, Colell A. Mitochondrial cholesterol loading exacerbates amyloid beta peptide-induced inflammation and neurotoxicity. J. Neurosci. 29(20), 6394–6405 (2009).
   Google Scholar
• Koldamova R, Staufenbiel M, Lefterov I. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280(52), 43224–43235 (2005).
   Google Scholar
• Wahrle SE, Jiang H, Parsadanian M et al. Deletion of Abca1 increases Ab deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280(52), 43236–43242 (2005).
   Google Scholar
• Grösgen S, Grimm MO, Friess P, Hartmann T. Role of amyloid beta in lipid homeostasis. Biochim. Biophys. Acta 1801(8), 966–974 (2010).
   Google Scholar
• Kivipelto M, Helkala EL, Hanninen T et al. Midlife vascular risk factors and late-life mild cognitive impairment: A populationbased study. Neurology 56(12), 1683–1689 (2001).
   Google Scholar
• Wolf H, Grunwald M, Kruggel F et al. Hippocampal volume discriminates between normal cognition; questionable and mild dementia in the elderly. Neurobiol. Aging 22(2), 177–186 (2001).
   Google Scholar
• Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch. Neurol. 59(3), 378–384 (2002).
   Google Scholar
• Kuo YM, Emmerling MR, Bisgaier CL et al. Elevated low-density lipoprotein in Alzheimer’s disease correlates with brain Abeta 1–42 levels. Biochem. Biophys. Res. Commun. 252(3), 711–715 (1998).
   Google Scholar
• Shie FS, Jin LW, Cook DG, Leverenz JB, Leboeuf RC. Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13(4), 455–459 (2002).
   Google Scholar
• Abad-Rodriguez J, Ledesma MD, Craessaerts K et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J. Cell. Biol. 167(5), 953–960 (2004).
   Google Scholar
• Mielke MM, Zandi PP, Shao H et al. The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology 75(21), 1888–1895 (2010).
   Google Scholar
• Reitz C. Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations. J. Alzheimers Dis. doi:10.3233/JAD-2011-110599 (2011) (Epub ahead of print).
   Google Scholar
• Reitz C, Luchsinger J, Tang MX, Manly J, Mayeux R. Impact of plasma lipids and time on memory performance in healthy elderly without dementia. Neurology 64(8), 1378–1383 (2005).
   Google Scholar
• Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch. Neurol. 61(5), 705–714 (2004).
   Google Scholar
• Reitz J, Gehrig-Burger K, Strauss JF, Gimpl G. Cholesterol interaction with the related steroidogenic acute regulatory lipid-transfer (START) domains of StAR (STARD1) and MLN64 (STARD3). FEBS J. 275(8), 1790–1802 (2008).
   Google Scholar
• Mielke MM, Zandi PP, Sjogren M et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64(10), 1689–1695 (2005).
   Google Scholar
• Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 68(10), 1239–1244 (2011).
   Google Scholar
• Refolo LM, Malester B, Lafrancois J et al. Hypercholesterolemia accelerates the Alzheimer’s amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 7(4), 321–331 (2000).
   Google Scholar
• Sparks DL. Intraneuronal beta-amyloid immunoreactivity in the CNS. Neurobiol. Aging 17(2), 291–299 (1996).
   Google Scholar
• Panza F, D’Introno A, Colacicco AM et al. Lipid metabolism in cognitive decline and dementia. Brain Res. Rev. 51(2), 275–292 (2006).
   Google Scholar
• Bjorkhem I, Lutjohann D, Breuer O, Sakinis A, Wennmalm A. Importance of a novel oxidative mechanism for elimination of brain cholesterol. Turnover of cholesterol and 24(S)-hydroxycholesterol in rat brain as measured with 18O2 techniques in vivo and in vitro. J. Biol. Chem. 272(48), 30178–30184 (1997).
   Google Scholar
• Lutjohann D, Breuer O, Ahlborg G et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl Acad. Sci. USA 93(18), 9799–9804 (1996).
   Google Scholar
• Lund EG, Guileyardo JM, Russell DW. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl Acad. Sci. USA 96(13), 7238–7243 (1999).
   Google Scholar
• Bretillon L, Thuret G, Gregoire S et al. Lipid and fatty acid profile of the retina, retinal pigment epithelium/choroid, and the lacrimal gland, and associations with adipose tissue fatty acids in human subjects. Exp. Eye Res. 87(6), 521–528 (2008).
   Google Scholar
• Babiker A, Andersson O, Lund E et al. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. Comparison with high density lipoprotein-mediated reverse cholesterol transport. J. Biol. Chem. 272(42), 26253–26261 (1997).
   Google Scholar
• Meaney S, Heverin M, Panzenboeck U et al. Novel route for elimination of brain oxysterols across the blood–brain barrier: conversion into 7alpha-hydroxy-3-oxo-4-cholestenoic acid. J. Lipid. Res. 48(4), 944–951 (2007).
   Google Scholar
• Famer D, Meaney S, Mousavi M, Nordberg A, Bjorkhem I, Crisby M. Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. Biochem. Biophys. Res. Commun. 359(1), 46–50 (2007).
   Google Scholar
• Leoni V, Masterman T, Mousavi FS et al. Diagnostic use of cerebral and extracerebral oxysterols. Clin. Chem. Lab. Med. 42(2), 186–191 (2004).
   Google Scholar
• Papassotiropoulos A, Lutjohann D, Bagli M et al. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 36(1), 27–32 (2002).
   Google Scholar
• Blennow K, Hampel H. CSF markers for incipient Alzheimer’s disease. Lancet Neurol. 2(10), 605–613 (2003).
   Google Scholar
• Leoni V, Shafaati M, Salomon A, Kivipelto M, Bjorkhem I, Wahlund LO. Are the CSF levels of 24S-hydroxycholesterol a sensitive biomarker for mild cognitive impairment? Neurosci. Lett. 397(1–2), 83–87 (2006).
   Google Scholar
• Yau JL, Rasmuson S, Andrew R et al. Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer’s disease. Neuroscience 121(2), 307–314 (2003).
   Google Scholar
• Mateos L, Akterin S, Gil-Bea FJ et al. Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro. Brain Pathol. 19(1), 69–80 (2009).
   Google Scholar
• Janowski BA, Grogan MJ, Jones SA et al. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl Acad. Sci. USA 96(1), 266–271 (1999).
   Google Scholar
• Cao G, Bales KR, Demattos RB, Paul SM. Liver X receptor-mediated gene regulation and cholesterol homeostasis in brain: relevance to Alzheimer’s disease therapeutics. Curr. Alzheimer Res. 4(2), 179–184 (2007).
   Google Scholar
• Vanmierlo T, Rutten K, Dederen J et al. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol. Aging 32(7), 1262–1272 (2011).
   Google Scholar
• Qing H, He G, Ly PT et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer’s disease mouse models. J. Exp. Med. 205(12), 2781–2789 (2008).
   Google Scholar
• Hudry E, Van Dam D, Kulik W et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s disease. Mol. Ther. 18(1), 44–53 (2010).
   Google Scholar
• Bryleva EY, Rogers MA, Chang CCY et al. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl Acad. Sci. USA 107(7), 3081–3086 (2010).
   Google Scholar
• Heverin M, Bogdanovic N, Lutjohann D et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J. Lipid Res. 45(1), 186–193 (2004).
   Google Scholar
• Shafaati M, Marutle A, Pettersson H et al. Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer’s patients with the Swedish APP 670/671 mutation. J. Lipid Res. 52(5), 1004–1010 (2011).
   Google Scholar
• Dasari B, Prasanthi JRP, Marwarha G, Singh BB, Ghribi O. The oxysterol 27-hydroxycholesterol increases beta-amyloid and oxidative stress in retinal pigment epithelial cells. BMC Ophthalmology 10, 22 (2010).
   Google Scholar
• Vetrivel KS, Thinakaran G. Membrane rafts in Alzheimer’s disease beta-amyloid production. Biochim. Biophys. Acta 1801(8), 860–867 (2010).
   Google Scholar
• Thelen KM, Laaksonen R, Paiva H, Lehtimaki T, Lutjohann D. High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J. Clin. Pharmacol. 46(7), 812–816 (2006).
   Google Scholar
• Tsuji A. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood–brain barrier. Ther. Drug Monit. 20(5), 588–590 (1998).
   Google Scholar
• Fassbender K, Simons M, Bergmann C et al. Simvastatin strongly reduces levels of Alzheimer’s disease beta-amyloid peptides Abeta42 and Abeta40 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98(10), 5856–5861 (2001).
   Google Scholar
• Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 356(9242), 1627–1631 (2000).
   Google Scholar
• Lütjohann D, Von Bergmann K. 24S-hydroxycholesterol: a marker of brain cholesterol metabolism. Pharmacopsychiatry 36, S102–S106 (2003).
   Google Scholar
• Refolo LM, Pappolla MA, Lafrancois J et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer’s disease. Neurobiol. Dis. 8(5), 890–899 (2001).
   Google Scholar
• Buxbaum JD, Geoghagen NS, Friedhoff LT. Cholesterol depletion with physiological concentrations of a statin decreases the formation of the Alzheimer amyloid Abeta peptide. J. Alzheimers Dis. 3(2), 221–229 (2001).
   Google Scholar
• Tamboli IY, Barth E, Christian L et al. Statins promote the degradation of extracellular amyloid beta-peptide by microglia via stimulation of exosome-associated insulindegrading enzyme (IDE) secretion. J. Biol. Chem. 285(48), 37405–37414 (2010). Describes interesting data regarding statin use for the promotion of amyloid-b degradation.
   Google Scholar
• McGuinness B, Passmore P. Can statins prevent or help treat Alzheimer’s disease? J. Alzheimers Dis. 20(3), 925–933 (2010).
   Google Scholar
• Sturgeon JD, Folsom AR, Longstreth WTJ, Shahar E, Rosamond WD, Cushman M. Hemostatic and inflammatory risk factors for intracerebral hemorrhage in a pooled cohort. Stroke 39(8), 2268–2273 (2008).
   Google Scholar
• Michikawa M, Yanagisawa K. Apolipoprotein E4 induces neuronal cell death under conditions of suppressed de novo cholesterol synthesis. J. Neurosci. Res. 54(1), 58–67 (1998).
   Google Scholar
• Meske V, Albert F, Richter D, Schwarze J, Ohm TG. Blockade of HMG-CoA reductase activity causes changes in microtubulestabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer’s disease. Eur. J. Neurosci. 17(1), 93–102 (2003).
   Google Scholar
• Treiber-Held S, Distl R, Meske V, Albert F, Ohm TG. Spatial and temporal distribution of intracellular free cholesterol in brains of a Niemann–Pick type C mouse model showing hyperphosphorylated tau protein. Implications for Alzheimer’s disease. J. Pathol. 200(1), 95–103 (2003).
   Google Scholar
• Kandiah N, Feldman HH. Therapeutic potential of statins in Alzheimer’s disease. J. Neurol. Sci. 283(1–2), 230–234 (2009).
   Google Scholar
• Shepardson NE, Shankar GM, Selkoe DJ. Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch. Neurol. 68(11), 1385–1392 (2011).
   Google Scholar